6CM
IMVT icon

683 Capital Management’s Immunovant IMVT Stock Holding History

683 Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-13,400
Closed -$213K – 163
2019
Q4 		$213K Sell
13,400
-786,600
-98% -$8.81M 0.02% 98
2019
Q3 		$8.02M Buy
+800,000
New +$7.9M 0.89% 31

Other funds holding IMVT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

683 Capital Management's IMVT Position: Q1 2020 in Review

683 Capital Management sold out of Immunovant (IMVT) in Q1 2020, closing a stake of 13,400 shares — an estimated $213K sold.

683 Capital Management first reported a position in IMVT in Q3 2019 and held it in 2 quarters. The position peaked at $8.02M in Q3 2019. 40 funds tracked by Wall St. Rank hold IMVT as of Q1 2020.

  • 683 Capital Management reported no remaining Immunovant position as of Q1 2020 after selling out during the quarter.
  • 683 Capital Management sold 13,400 Immunovant shares in Q1 2020, an estimated $213K.
  • 683 Capital Management first reported a position in Immunovant in Q3 2019 and held it in 2 quarters.
  • 683 Capital Management's Immunovant position peaked at $8.02M in Q3 2019.
  • 40 funds tracked by Wall St. Rank held Immunovant as of Q1 2020.

Based on 683 Capital Management's 13F filing for Q1 2020, filed 15 May 2020.